Comparable Outcomes of Pre- Versus Post-Tyrosine Kinase Inhibitor Era Treatment in Chronic Myeloid Leukemia: A Retrospective Cohort Study With Long-term Follow-up

Imatinib, a selective BCR-ABL tyrosine kinase inhibitor (TKI), was introduced after allogeneic hematopoietic stem cell transplantation (allo-HSCT) for patients with chronic myeloid leukemia (CML). However, the long-term effects of allo-HSCT in chronic phase CML patients are mostly unknown. We retros...

Full description

Bibliographic Details

Published in:	Cell Transplantation
Main Authors:	Sahar Tavakoli, Fattaneh Khalaj, Amir Kasaeian, Seyed Ali Mousavi, Amir-Hossein Mousavian, Fatemeh Arabi, Soroush Rad, Shahrbano Rostami, Maryam Barkhordar, Mohammad Biglari, Heydar Ali Mardani-Fard, Hediyeh Alemi, Naghmeh Khavandgar, Hossein Kamranzadeh Fumani, Ghasem Janbabai, Seied Asadollah Mousavi, Ardeshir Ghavamzadeh, Mohammad Vaezi
Format:	Article
Language:	English
Published:	SAGE Publishing 2023-04-01
Online Access:	https://doi.org/10.1177/09636897231163212